LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

2003: Human Genome Project completion

18/06/2021

Nominated by: Voisin Consulting Life Sciences

Launched in 1990, the Human Genome project was an unprecedented international scientific research project with the primary goal to discover the complete set of human genes and determine the complete sequence of DNA bases in the human genome.

It was the world’s largest collaborative project, with global contributions, multiple funding sources and dedicated research centres in the US, UK, Japan, China, Germany and France.

A key driver of the HGP was the requirement of all data to be publicly available to ensure unrestricted access for scientists.

The project remarkably determined that the human genome is nearly identical between any two individuals and a single nucleotide change can be responsible for causing human disease, contributing to our understanding of the molecular mechanisms underlying a multitude of human diseases and focused our understanding of proteomics.

The project was declared complete in 2003, however gaps remained, which were filled in subsequent years, with the latest publication in 2021 from the Telomere to Telomere consortium establishing an almost complete human genome.

It was the world’s most significant project within biotechnology and was driven in part through competition with a private sequencing initiative from US company Celera, which intended to patent a number of genes and would not allow free use or distribution of genome data.   The speed of Human Genome Project was driven by the need to publish findings into the public domain before the Celera initiative was able to protect and restrict access through its own results.

The impact of the HGP on biotechnology cannot be over-estimated.  It has shaped our understanding of human genetics and disease, impacting public policy, research and medicines development and marked the dawn of ‘big data’ as a central pilar of biotechnology advances world-wide. It also marked the huge achievements possible through collaborative science. Finally, it revolutionised the technologies used in genetic sequencing, with first generation capability rapidly accelerating to enable faster, cheaper and more accessible sequencing to an everyday research tool. It is debatable that none of the advances that biotechnology yields today would be possible without the Human Genome Project.

References:

  • 1.Human Genome Project Information, 1990-2003
  • 2. European ”1+Million Genomes Initiative”
  • 3. Cordis EU Research results database

 

Back to the list.

Share
Alexandra Simionca
Alexandra Simionca
EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.